Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has issued an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced its 2024 annual report, highlighting a consolidated net profit of RMB 2.84 billion attributable to shareholders. The company proposed a cash dividend of RMB 0.40 per share, amounting to a total of RMB 650.32 million, with undistributed profits carried forward. This financial performance and profit distribution plan reflect the company’s stable position in the pharmaceutical industry and its commitment to rewarding shareholders.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company is a joint stock company with limited liability established in China. It operates in the pharmaceutical industry, focusing on the production and distribution of medical and healthcare products. The company has several subsidiaries, including Baiyunshan Han Fang, Baiyunshan Hospital, and Baiyunshan Jianhu Company, which are involved in contemporary pharmaceuticals, hospital management, and medical products.
YTD Price Performance: 3.49%
Average Trading Volume: 30,548
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.82B
See more data about 0874 stock on TipRanks’ Stock Analysis page.